Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.42
+0.25 (1.03%)
Aug 5, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Employees
Denali Therapeutics had 507 employees as of March 31, 2026. The number of employees increased by 64 or 14.45% compared to the same quarter last year.
Employees
507
Change
64
Growth
14.45%
Revenue / Employee
n/a
Profits / Employee
-$1,002,006
Market Cap
3.88B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 507 | 64 | 14.45% |
| Dec 31, 2025 | 503 | 81 | 19.19% |
| Sep 30, 2025 | 517 | 127 | 32.56% |
| Jun 30, 2025 | 486 | 122 | 33.52% |
| Mar 31, 2025 | 443 | 68 | 18.13% |
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Sep 30, 2024 | 390 | -57 | -12.75% |
| Jun 30, 2024 | 364 | -74 | -16.89% |
| Mar 31, 2024 | 375 | -55 | -12.79% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Sep 30, 2023 | 447 | 34 | 8.23% |
| Jun 30, 2023 | 438 | 43 | 10.89% |
| Mar 31, 2023 | 430 | 50 | 13.16% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Sep 30, 2022 | 413 | 53 | 14.72% |
| Jun 30, 2022 | 395 | 61 | 18.26% |
| Mar 31, 2022 | 380 | 69 | 22.19% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Arcutis Biotherapeutics | 354 |
| Structure Therapeutics | 233 |
| Alumis | 227 |
| Relay Therapeutics | 193 |
| IDEAYA Biosciences | 145 |
DNLI News
- 2 days ago - Denali Therapeutics treatment of frontotemporal dementia granted orphan status - TheFly
- 9 days ago - Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - GlobeNewsWire
- 13 days ago - Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley - TheFly
- 20 days ago - Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank - TheFly
- 22 days ago - Denali Therapeutics falls -14.1% - TheFly
- 22 days ago - Denali Therapeutics falls -12.4% - TheFly
- 23 days ago - Denali Therapeutics price target raised to $26 from $20 at Wedbush - TheFly
- 23 days ago - Denali Therapeutics resumed with an Overweight at JPMorgan - TheFly